...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lab on a chip >Microfluidic device for expedited tumor growth towards drug evaluation
【24h】

Microfluidic device for expedited tumor growth towards drug evaluation

机译：用于加速肿瘤生长的微流体装置对药物评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patient derived organoids have emerged as robust preclinical models for screening anti-cancer therapeutics. Current 2D culturing methods do not provide physiological responses to therapeutics, therefore 3D models are being developed to better reproduce physiological responses. 3D culturing however often requires large initial cell populations and one week to one month to grow tumors ready for therapeutic testing. As a solution a 3D culturing system has been developed capable of producing physiologically relevant tumors in an expedited fashion while only requiring a small number of initial cancer cells. A bi-layer microfluidic system capable of facilitating active convective nutrient supply to populations of cancer cells facilitates expedited growth of cancer cells when starting with populations as small as 8 cells. The system has been shown to function well with adherent and non-adherent cell types by expediting cell growth by a factor ranging from 1.27 to 4.76 greater than growth under static conditions. Utilizing such an approach has enable to formation of tumors ready for therapeutic screening within 3 days and the ability to perform therapeutic screening within the microfluidic system is demonstrated. A mathematical model has been developed which allows for adjustments to be made to the dynamic delivery of nutrients in order to efficiently use culture media without excessive waste. We believe this work to be the first attempt to grow cancers in an expedited fashion utilizing only a convective nutrient supply within a microfluidic system which also facilitates on-device therapeutic screening. The developed microfluidic system and cancer growth method have the potential to offer improved drug screening for patients in clinical settings.
机译：患者衍生的有机体被出现为筛选抗癌治疗的鲁棒临床前模型。目前的2D培养方法不提供治疗剂的生理反应，因此正在开发3D模型以更好地再现生理反应。然而，3D培养通常需要大的初始细胞群，一周至一个月，以便为治疗测试做好准备。作为解决方案，已经开发了一种能够以加速方式生产生理相关肿瘤的3D培养系统，同时仅需要少量初始癌细胞。能够促进对癌细胞群体的活性对流营养供应的双层微流体系统有助于在与8个细胞的群体开始时加速癌细胞生长。该系统已被证明通过加速细胞生长的粘附剂和非粘附细胞类型良好，其因子在1.27至4.76中大于静态条件下的生长。利用这种方法可以在3天内形成准备用于治疗性筛选的肿瘤，并证明在微流体系统内进行治疗筛选的能力。已经开发了一种数学模型，其允许调节营养成分的动态传递，以便有效地使用培养基而没有过度浪费。我们认为，这项工作是第一次尝试在加速时装中生长癌症，仅在微流体系统内使用对流营养供应，该系统还促进了设备的治疗性筛选。发育的微流体系统和癌症生长方法有可能为临床环境中的患者提供改善的药物筛选。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号